Coldstream Capital Management Inc. Acquires 427 Shares of Natera, Inc. $NTRA

Coldstream Capital Management Inc. increased its holdings in Natera, Inc. (NASDAQ:NTRA) by 17.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,849 shares of the medical research company’s stock after purchasing an additional 427 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Natera were worth $481,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the business. Bank of Jackson Hole Trust bought a new position in shares of Natera during the first quarter valued at about $29,000. Northwestern Mutual Wealth Management Co. boosted its holdings in Natera by 83.5% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 106 shares during the period. Hilltop National Bank bought a new position in Natera during the 2nd quarter worth approximately $33,000. Oliver Lagore Vanvalin Investment Group bought a new position in Natera during the 2nd quarter worth approximately $36,000. Finally, Summit Securities Group LLC purchased a new position in Natera in the 1st quarter worth approximately $39,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Trading Up 0.3%

Shares of NASDAQ NTRA opened at $237.12 on Friday. The firm has a fifty day simple moving average of $191.21 and a two-hundred day simple moving average of $170.04. Natera, Inc. has a 12 month low of $125.38 and a 12 month high of $241.28. The firm has a market capitalization of $32.72 billion, a PE ratio of -103.55 and a beta of 1.75.

Natera (NASDAQ:NTRA) last announced its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The company had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. During the same period in the previous year, the firm posted ($0.26) EPS. The company’s revenue for the quarter was up 34.7% on a year-over-year basis. On average, sell-side analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. UBS Group increased their price objective on Natera from $218.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. BNP Paribas Exane upgraded shares of Natera from an “underperform” rating to a “neutral” rating and set a $172.00 price target for the company in a report on Monday, October 27th. Morgan Stanley raised their price target on shares of Natera from $195.00 to $220.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Zacks Research cut shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Monday, October 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Wednesday, October 8th. Fifteen analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and an average target price of $220.88.

Insider Buying and Selling at Natera

In other news, Director Roy D. Baynes sold 7,668 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $223.08, for a total value of $1,710,577.44. Following the completion of the transaction, the director owned 18,359 shares in the company, valued at $4,095,525.72. This trade represents a 29.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 160,703 shares of Natera stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $199.96, for a total value of $32,134,171.88. Following the sale, the chief executive officer owned 144,816 shares in the company, valued at $28,957,407.36. This represents a 52.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 308,366 shares of company stock worth $63,050,068. Insiders own 5.63% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.